al102
·Code: BMS-986115
al102: developed by 1 company · 1 clinical trial tracked.
al102 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect al102 to AYLA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could al102 → AYLA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Multiple myeloma (MM)Desmoid Tumor
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| OLD AYALA, INC (AYLA) Multiple myeloma (MM) | Preclinical |
Clinical Trials (1)
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
Primary endpoint: Part A: Safety and Tolerability - Adverse Events
InterventionalRandomizedquadruple198 enrolledStarted 2021-09Completion 2026-1250 sites · Australia, Belgium, Germany, Israel…Immunome, Inc.
Frequently asked questions
Who is developing al102?
al102 is being developed by OLD AYALA, INC.
How many clinical trials involve al102?
BioSniper tracks 1 clinical trial involving al102.